TP53 and neuroendocrine carcinoma: Moreover, it is worth noting that a previous study has shown that 35% of pancreatic NET (PanNET) G3 cases may also have alterations in TP53, which further aggravates the role of the pathologist in distinguishing high-grade NENs into NET G3 and NEC (16).